【researchmap】
https://researchmap.jp/C_Nakaseko

1. 1.Hasegawa N, Oshima M, Nakaseko C, et al. Impact of combinatorial dysfunctions in epigenetic regulators Tet2 and Ezh2 on the epigenome in the pathogenesis of myelodysplastic syndrome. Leukemia 2017; 31(4):861-71.
2. 2.Togasaki E, Takeda J, Nakaseko C, et al. for the Japan Adult Leukemia Study Group (JALSG). Frequent somatic mutations in epigenetic regulators in newly-diagnosed chronic myeloid leukemia. Blood Cancer J 2017;7(4):e559.
3. 3.Muto T, Ohwada C, Nakaseko C et al. Safety and efficacy of granulocyte-colony stimulating factor monotherapy for peripheral blood stem cell collection in POEMS Syndrome. Biol Blood Marrow Transplant 2017;23(2):361-3
4. 4.Rizq O, Mimura N, Nakaseko C et al, Iwama A. Dual inhibition of EZH2/1 sensitizes PRC2-dependent tumors to proteasome inhibition. Clin Cancer Res. 2017 May 10. [Epub ahead of print]
5. 5.Takahashi N, Nakaseko C, Kobayashi Y, et al. Long-term treatment with bosutinib in a phase 1/2 study in Japanese chronic myeloid leukemia patients resistant/intolerant to prior tyrosine kinase inhibitor treatment. Int J Hematol 2017 Apr 13. [Epub ahead of print]